Resveratrol's promise as an anti-aging compound was based on SIRT1 activation (later disputed in mechanism) and lifespan extension in simple organisms. Human clinical trials have consistently failed to replicate benefits observed in animal models, primarily because resveratrol's oral bioavailability in humans is <1% — making plasma concentrations far below the concentrations producing biological effects in vitro.

Is resveratrol a waste of money?

For the typical 100–200 mg/day doses in most supplements, yes — plasma levels are too low to replicate animal model effects. If taking resveratrol, use high-dose formats (500+ mg) or switch to pterostilbene for reliably higher bioavailability.

Did Sinclair's resveratrol research mislead people?

The science was conducted in good faith; translation from simple organisms to humans encountered the common problem of poor human bioavailability. The SIRT1 mechanism question is ongoing. Sinclair has since shifted focus to NMN and other compounds.